PRF Technologies (PRFX) Long-Term Deferred Tax (2019 - 2020)
PRF Technologies (PRFX) posted quarterly Long-Term Deferred Tax of $3.5 million for Q4 2020, up 16.18% year-on-year from $3.0 million in Q1 2020, and up 16.18% on a QoQ basis from $3.0 million in Q4 2019.
PRF Technologies (PRFX) Long-Term Deferred Tax (2019 - 2020) Analysis & Trends
PRF Technologies (PRFX) has reported Long-Term Deferred Tax for 2 consecutive years, with $3.5 million the latest figure, recorded in Q4 2020.
- Quarterly Long-Term Deferred Tax rose 16.18% year-over-year to $3.5 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $3.5 million (up 16.18% YoY) and the FY2020 annual result came in at $3.5 million, up 16.18% from the prior year.
- Long-Term Deferred Tax climbed to $3.5 million in Q4 2020 per PRFX's latest filing, from $3.0 million in the prior quarter.
- Over the last five years, Long-Term Deferred Tax for PRFX reached as high as $3.5 million in Q4 2020 and fell as low as $3.0 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | PRF Technologies | 745,168.93 | 451,168.93 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 3.48 Mn |
| Dec 31, 2019 | 2.99 Mn |